Back to Search Start Over

Blood safety and the choice of anti-hemophilic factor concentrate.

Authors :
Valentino LA
Oza VM
Source :
Pediatric blood & cancer [Pediatr Blood Cancer] 2006 Sep; Vol. 47 (3), pp. 245-54.
Publication Year :
2006

Abstract

Hemophilia is a congenital disorder due to the deficiency of the activity of factor VIII (classical hemophilia A) or IX (Christmas disease or hemophilia B). Bleeding is common and may result in long-term complications or even death. Bleeding may be treated or prevented by infusion of factor concentrates however these drugs are not without risk. Clinicians often feel ill prepared to provide accurate and impartial information regarding these drugs. This review will provide the reader with an historical yet up to date perspective on blood safety as it relates to the choice of concentrates to treat hemophilia.

Details

Language :
English
ISSN :
1545-5009
Volume :
47
Issue :
3
Database :
MEDLINE
Journal :
Pediatric blood & cancer
Publication Type :
Academic Journal
Accession number :
16724312
Full Text :
https://doi.org/10.1002/pbc.20895